Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Phase Ib Dose Escalation Trial of Oral Combination Therapy With MSC1936369B and SAR245409 in Subjects With Locally Advanced or Metastatic Solid Tumors

NCT01390818 is registered in ClinicalTrials.gov with EMD Serono as lead sponsor.

NCT NCT01390818
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01390818 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Phase Ib Dose Escalation Trial of Oral Combination Therapy With MSC1936369B and SAR245409 in Subjects With Locally Advanced or Metastatic Solid Tumors
Lead sponsor
EMD Serono
Phase
Phase 1
Overall status
Completed
Start date
May 31, 2011
Completion date
April 30, 2015
Enrollment
146 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, colorectal cancer, locally advanced solid tumor, melanoma, metastatic solid tumor, non small cell lung cancer